The FDA approved CSL Behring’s long-acting recombinant albumin fusion protein, Idelvion, for use in children and adults with hemophilia B (also called congenital factor IX deficiency or Christmas disease). 
MARCH 8, 2016
FDA Approves Idelvion for Hemophilia B
By PPN News Staff
Idelvion (coagulation factor IX [recombinant], albumin fusion protein) is the first and only factor IX therapy that delivers high-level protection with up to 14-day dosing in appropriate patients. This dosing interval has been achieved while maintaining high